Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of Zevotrelvir (EDP-235)
NCT05246878Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zevotrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Safety measured by adverse events in SAD Cohorts at 8 days and Safety measured by adverse events in MAD Cohorts at 14 days. Started Jan 2022; status: completed.
02
Drugs
zevotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05246878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246878.